New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
09:14 EDTOXGNOxigene regains compliance with NASDAQ listing rule
Oxigene announced that on January 14 Nasdaq notified the company that it regained compliance with the minimum $1.00 per share closing bid price requirement for continued listing. As a result of satisfying the minimum bid price requirement, this matter is now closed.
News For OXGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2014
16:03 EDTOXGNOXiGENE announces first patient enrolled in phase 1b/2 study of Fosbretabulin
OXiGENE announced that the first patient has been enrolled in a phase 1b/2 clinical study that will evaluate fosbretabulin in combination with Votrient in patients with recurrent ovarian cancer. The randomized, controlled clinical study consists of a phase 1b dose escalation portion with the combination of fosbretabulin and pazopanib and a phase 2 portion comparing fosbretabulin and pazopanib versus pazopanib alone. The study is estimated to enroll up to 128 patients at sites in the United Kingdom. The primary endpoint is progression-free survival, and secondary endpoints include safety, overall survival, objective response rate and relevant biomarkers.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use